GLTO - Galecto - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-11.83M

Cash

27.17M

Avg Qtr Burn

-8.428M

Short % of Float

0.01%

Insider Ownership

11.80%

Institutional Own.

20.06%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GB1211 (oral galectin-3 inhibitor) + pembrolizumab (Keytruda®) Details Cancer, Melanoma, Head and neck squamous cell carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1211 (oral galectin-3 inhibitor) Details Non-alcoholic steatohepatitis , Cirrhosis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details Non-small cell lung carcinoma, Cancer, Fibrosis	Phase 2a Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB2064 (oral LOXL2 inhibitor) Details Fibrosis, Myelofibrosis	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB0139 (inhaled galectin-3 inhibitor) Details Fibrosis, Pulmonary fibrosis, Lung disease, Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.